



Indraprastha Medical Corporation Limited

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi - 110 076. (INDIA)

Corporate Identity Number : L24232DL 1988PLC030958

Phone : 26925801, 26925858 Fax : 91-11-26825601

E-mail : asinghal@apollohospitals.com Website : apollohospdelhi.com



Accredited by
Joint Commission International

A. K. SINGHAL

Vice President
Cum Company Secretary

Ref: IMCL/CS/BM/2019

8th May, 2019

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy
Towers Dalal Street, Mumbai,
Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra - 400051
Symbol: INDRAMEDCO

Re: Outcome of the Board Meeting held on 8th May, 2019

Dear Sir,

Pursuant to provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) we wish to inform you that the Board of Directors at its meeting held today i.e. on 8th May, 2019, have approved:

1. The Audited Financial results of the company for the quarter and financial year ended 31st March 2019.

Please find enclosed audited financial results for the quarter and financial year ended 31st March, 2019 along with a copy of the unmodified Audit Report by the Statutory Auditors of the Company.

In terms of second proviso to regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, a declaration by CFO confirming that the Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year ended 31st March 2019, is also enclosed.

2. Recommendation of Dividend

Pursuant to Regulation 30 & 43 of the Listing Regulations, we wish to inform you that the Board of Directors of the Company, recommended the payment of dividend @ 16% i.e. Rs. 1.60 per share for the financial year 2018-19.

Dividend if approved by the shareholders will be paid on or before 30th October, 2019.

The Board meeting commenced at 3.00 p.m. and ended at 6.25 p.m.
This is for your information and record.

Thanking You,
Sincerely Yours,


A.K.SINGHAL

Encl. As above

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Indraprastha Medical Corporation Limited

We have audited the accompanying statement of financial results of **Indraprastha Medical Corporation Limited** ("the Company") for the quarter and year ended 31 March, 2019 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated 5 July 2016.


Attention is drawn to the fact that the figures for the quarter ended 31 March, 2019 as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to an audit. This Statement has been prepared on the basis of the reviewed quarterly financial results up to the end of the third quarter, the audited annual financial statements as at and for the year ended 31 March, 2019, and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which is the responsibility of the Company's management and have been approved by the Board of Directors of the Company.

Our responsibility is to express an opinion on the Statement based on our review of financial results for the nine months period ended 31 December, 2018, which was prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', issued pursuant to Companies (Indian Accounting Standards) Rules, 2015 as specified in Section 133 of the Companies Act, 2013 read with SEBI Circular dated 5 July 2016 and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended 31 March, 2019; and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

Based on our audit conducted as above, in our opinion and to the best of our information and according to the explanations given to us, the accompanying Statement:

- (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5 July 2016 in this regard; and



(ii) give a true and fair view of the net profit (financial performance including other comprehensive income) and other financial information for the quarter and year ended 31 March, 2019.

For **S.N. Dhawan & CO LLP**

Chartered Accountants

Firm Registration No.: 000050N/N500045



Rajeev K Saxena

Partner

Membership No.: 077974

New Delhi: 8th May, 2019

Statement of Audited Financial Results for the Quarter and year ended 31st March, 2019

S. No.	Particulars	Quarter ended			Amount (Rs. in million)	
		31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Revenue from operations	2004.23	1981.97	1899.52	7881.72	7526.60
2	Other Income	2.25	0.85	0.65	4.67	7.91
3	Total income	2006.48	1982.82	1900.17	7886.39	7534.51
4	Expenses					
	a) Cost of material consumed	371.57	356.00	340.54	1449.62	1398.40
	b) Employee benefits expense	509.09	515.29	505.82	2002.05	1940.14
	c) Professional charges to doctors	488.17	495.55	473.23	1975.55	1937.65
	d) Finance cost	15.32	18.24	20.75	68.71	88.99
	e) Depreciation and amortisation expense	71.78	74.73	75.90	297.54	306.82
	f) Other expenses	440.56	411.61	381.70	1646.71	1522.46
	Total expenses	1896.49	1871.42	1797.94	7440.18	7194.46
5	Profit before exceptional items and tax	109.99	111.40	102.23	446.21	340.05
6	Exceptional items	-	-	-	-	-
7	Profit before tax (PBT)	109.99	111.40	102.23	446.21	340.05
8	Tax expense					
	Current tax	42.04	39.46	60.92	185.28	139.31
	Deferred tax	(3.40)	0.76	(14.50)	(23.20)	(10.29)
9	Profit for the period after tax (PAT)	71.35	71.18	55.81	284.13	211.03
10	Other comprehensive income					
	a). (i) Items that will not be reclassified to profit or loss	4.41	(8.00)	(3.93)	(1.72)	3.73
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	(1.54)	2.80	1.35	0.60	(1.30)
	Total other comprehensive income, Net of tax expenses	2.87	(5.20)	(2.58)	(1.12)	2.43
11	Total comprehensive income for the period	74.22	65.98	53.23	283.01	213.46
12	Paid-up equity share capital (Face value Rs. 10/- each)	916.73	916.73	916.73	916.73	916.73
13	Earnings per share Basic and Diluted (Rs.)	0.78	0.78	0.61	3.10	2.30



ABaypai

2. The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 8th May, 2019.
3. The Board of Directors have recommended dividend @16% (Rs. 1.60/- per share) for the financial year 2018-19.
4. The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
5. Previous year/period figures have been regrouped / rearranged wherever necessary. The figures for the last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.

Place : New Delhi
Date : 8th May, 2019



A. Bajpai
Ashok Bajpai
Managing Director

Notes:

1. Statement of Assets and Liabilities		As at	As at
Particulars		31 st March	31 st March
		2019	2018
ASSETS			
1	Non-current assets		
	(a) Property, Plant and Equipment		
	(b) Capital work-in-progress	2796.67	2927.74
	(c) Intangible Assets	12.57	-
	(d) Financial Assets	4.31	11.90
	(e) Other non-current Assets	15.50	20.51
		39.09	33.56
	Total of Non-current assets		
		2868.14	2993.71
2	Current assets		
	(a) Inventories		
	(b) Financial Assets	83.16	91.24
	(i) Trade receivables		
	(ii) Cash and cash equivalents	762.02	844.74
	(iii) Bank Balances other than (ii) above	168.18	25.16
	(iv) Loans	56.18	54.25
	(v) Others	3.23	3.99
	(c) Current Tax Assets (Net)	56.08	63.70
	(d) Other current assets	47.42	77.63
		179.27	168.31
	Total of Current assets		
		1355.54	1329.02
	TOTAL OF ASSETS		
		4223.68	4322.73
EQUITY AND LIABILITIES			
1	Equity		
	(a) Equity Share capital		
	(b) Other Equity	916.73	916.73
	Total of Equity	1523.63	1406.40
		2440.36	2323.13
	Liabilities		
2	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings		
	(ii) Other Financial liabilities	150.00	210.00
	(b) Provisions	20.38	20.41
	(c) Deferred tax liabilities (Net)	98.19	87.30
	Total of Non-current liabilities	273.80	297.60
		542.37	615.31
3	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings		
	(ii) Trade payables	2.90	385.57
	- Total outstanding dues of micro and small enterprises		
	- Total outstanding dues of creditors other than micro and small enterprises	4.19	-
	(iii) Other financial liabilities	905.61	713.43
	(b) Other current liabilities	96.25	76.45
	(c) Provisions	163.95	135.11
		68.05	73.73
	Total of Current liabilities		
		1240.95	1384.29
	TOTAL OF EQUITY AND LIABILITIES		
		4223.68	4322.73



ABayyar



Indraprastha Medical Corporation Limited

Regd. Office: Sarita Vihar, Delhi-Mathura Road, New Delhi – 110 076 (India)

Corporate Identity Number: L24232DL1988PLC030958

Phone: 91-11-26925858, 26925801, Fax: 91-11-26823629

E-mail: imcl@apollohospitals.com, Website: apollohospdelhi.com



Ref: IMCL/CS/BM/2019

8th May, 2019

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy
Towers Dalal Street, Mumbai,
Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra – 400051
Symbol: INDRAMEDCO

Re: Declaration in terms of regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015

Dear Sir,

In terms of second proviso to regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we confirm that the Statutory Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year 2018-19.

Thanking you,

Yours faithfully,

For Indraprastha Medical Corporation Limited

C. P. Tyagi
Chief Financial Officer